Nausea on Zepbound (tirzepatide): Incidence, Severity, and Realistic Expectations

How common is nausea on Zepbound?

The Zepbound label pools two placebo-controlled trials, SURMOUNT-1 and SURMOUNT-2, in adults with obesity or overweight, with or without type 2 diabetes, treated for up to 72 weeks [1]. That pool covers 958 people on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg, all given once weekly by injection [1]. Nausea was reported by 25% of the 5 mg group, 29% of the 10 mg group and 28% of the 15 mg group, against 8% on placebo [1]. It is the first adverse reaction the label lists among those reported in at least 5% of treated patients [1].

The other gut reactions sit in the same band: diarrhea in 19%, 21% and 23% versus 8%; vomiting in 8%, 11% and 13% versus 2%; constipation in 17%, 14% and 11% versus 5%; abdominal pain in 9%, 9% and 10% versus 5%; indigestion in 9%, 9% and 10% versus 4% [1]. Counting every gastrointestinal complaint together, 56% of people at each Zepbound dose reported at least one, against 30% on placebo [1].

Nausea is common but far from universal: about seven in ten people on the 15 mg dose did not report it, and 8% of people injecting placebo reported nausea too [1].

How severe is the nausea, and how often does it end treatment?

The label reports severe gastrointestinal reactions and, separately, how often gastrointestinal reactions led people to stop treatment. These figures cover gastrointestinal reactions as a group, not nausea alone.

Severe gastrointestinal reactions were reported in 1.7% of the 5 mg group, 2.5% of the 10 mg group and 3.1% of the 15 mg group, versus 1% on placebo [1]. At any dose that is fewer than one person in thirty.

A gastrointestinal reaction led 1.9% of people on 5 mg, 3.3% on 10 mg and 4.3% on 15 mg to stop treatment, compared with 0.5% on placebo [1]. Any adverse reaction at all led 4.8%, 6.3% and 6.7% to stop versus 3.4% on placebo, and the label says the majority of those who stopped did so during the first few months of treatment because of gastrointestinal reactions [1]. In other words, roughly 96 of every 100 people at 15 mg did not stop Zepbound for a gastrointestinal reason [1].

When does it happen, and does it settle?

The label's description of timing is short and specific: the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [1].

Zepbound starts at 2.5 mg once weekly for 4 weeks, then goes to 5 mg, then rises in 2.5 mg steps after at least 4 weeks on the current dose; the 2.5 mg step is labelled initiation only and is not approved as a maintenance dose [1]. The label states that this escalation is followed to reduce the risk of gastrointestinal adverse reactions [1].

The label also reports that tirzepatide delays gastric emptying, with the delay largest after the first dose and diminishing over time [1]. The drug peaks at a median of 24 hours after injection, has a half-life of about 5 days, and reaches steady state after 4 weeks of weekly dosing [1].

Real-world data are consistent with the trial picture: a narrative review of observational studies found frequent gastrointestinal disturbances among users of GLP-1 receptor agonist weight-loss drugs, as also observed in trials [2].

Is nausea worse at higher doses?

Inside Zepbound's own weight-management trial pool, nausea was reported by 25% on 5 mg, 29% on 10 mg and 28% on 15 mg, versus 8% on placebo [1]. The rates do not climb in step with the dose: the 10 mg group reported slightly more nausea than the 15 mg group [1].

Every maintenance dose carried substantially more nausea than placebo, and the label places most events during dose escalation [1].

What the label says about a dose you cannot tolerate

The label gives one direct lever: choose the maintenance dose with tolerability in mind, and if patients do not tolerate a maintenance dose, consider a lower maintenance dose [1]. Maintenance doses for weight reduction are 5, 10 or 15 mg weekly, with a maximum of 15 mg [1].

The label also ties gastrointestinal side effects to specific warnings.

Volume depletion and kidney injury. Postmarketing reports describe acute kidney injury, in some cases requiring hemodialysis, with the majority of reported events in people whose nausea, vomiting or diarrhea caused dehydration; the label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during starting and dose escalation [1].

Gastroparesis. Zepbound is not recommended in patients with severe gastroparesis [1].

Pancreatitis. The label describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and says to discontinue Zepbound if pancreatitis is suspected [1].

Procedures. Pulmonary aspiration has been reported during general anesthesia or deep sedation in people taking GLP-1 receptor agonists, and the label asks patients to tell their providers about planned surgeries or procedures [1].

How does Zepbound compare with semaglutide?

The head-to-head obesity trial, SURMOUNT-5, randomized 751 adults to maximum tolerated tirzepatide (10 or 15 mg) or maximum tolerated semaglutide (1.7 or 2.4 mg) for 72 weeks; gastrointestinal events were the most common adverse events in both groups, and most were mild to moderate in severity [3].

For nausea numbers from a direct comparison, the closest published set comes from SURPASS-2, which randomized 1,879 adults with type 2 diabetes on metformin to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg for 40 weeks: nausea in 17% to 22% of the tirzepatide groups versus 18% with semaglutide 1 mg, diarrhea in 13% to 16% versus 12%, and vomiting in 6% to 10% versus 8% [4]. Those are diabetes doses in a diabetes population, not Zepbound against Wegovy, and the Zepbound label warns that rates from different trials cannot be compared directly [1].